May 2025

ON eNews

Welcome to this month's eNews



Tony Jones, CEO One Nucleus

Connecting for Success
What an exciting time it has been at One Nucleus of late. Hot on the heels of a busy March packed with celebration and showcasing, April continued the trend.

There and Back Again
Last week saw the 2025 Boston Bootcamp head to Massachusetts to connect and learn. We were blessed with an excellent set of winner companies: RNAvate, Metrion Biosciences, Tailor Bio, PharmEnable Therapeutics, and were joined by Cellestial Health and Outsee who travelled to be part of the group.

We are very grateful to the competition sponsors and visit hosts who have given generously to enable a huge amount of knowledge-sharing and plenty of food-for-thought to feed back to the wider One Nucleus ecosystem at ON Helix and beyond. We look forward to a return trip to Boston for the annual BIO Convention, RESI-Boston and One Nucleus satellite events in mid-June – watch this space!

Where Are Winners Forged?
I am pleased to see that, within this edition of eNews, readers will find links to articles looking at the science and business sides of successfully translating great bio-innovation into successful treatments and businesses. It was interesting when sharing insights between Cambridge and South Carolina at the recent seminar, how often connectivity, awareness, and a common vision is key to supporting bioentrepreneurs seeking to achieve the above.

This very much reflects recent thinking around the role of a membership group, such as One Nucleus, which I set out in the 'Creating the Home of Champions' blog linked below. The other articles covering advances in the science and multi-modal approaches via Domainex and Arctoris, leadership through the eyes of Priya Mande, and investment term sheet topics via HSBC Innovation Banking set out some of the opportunities and challenges on the journey from research to success which One Nucleus revels in supporting.

An Environment to Secure Excellence
The above journey, as we hear repeatedly, requires excellence at each stage. This is the reason all parts of the industry are vital, whether in science, investment or business operation strategies, and why One Nucleus endeavours to nurture an environment for deal flow. Whether in investment, R&D collaborations, outsourcing, recruitment, lab leasing, legal or other, these are all transactions to secure excellence that are required and which we seek to catalyse. A recurring theme on operational excellence has been dealing with the threats to cybersecurity in organisations. To better understand the current position of our network on these matters, we are conducting two brief surveys and would greatly value your input. The first survey concerns how cybersecurity due diligence is presently carried out in your supply chain choices. The second survey focusses on the people and training aspects. Your input would be welcome to help shape the support One Nucleus can offer.

Staying in the Loop
Remain informed of all One Nucleus updates, disseminate your company's news, or track the announcements from other members, and make full use of our website, LinkedIn, or X pages. The news stream contains numerous updates from our community. Enjoy the read!
Tony Jones, CEO, One Nucleus

Creating the Home of Champions
Continuing down the thought process of the importance of nurturing your local ambassadors to enable your international success described in last month's blog, Tony Jones' article explores the value of ensuring your company is not just recognised, but also well understood within your local ecosystem, since nurturing success is a two-way process between all parties. Read the article here.

An Adventurous Biotech CEO
Priya Mande, CEO of RNAvate, is leading the discussion on Biotech and Partnering Hotspots at BioBeat25. Organisers Anne Horgan, Partner at Cambridge Innovation Capital, Alisa Molotova, Start-up Mentor and Miranda Weston-Smith, BioBeat Founder, quiz her about how she got into her role. Find out more here.

Covalent Drug Discovery: Challenges, Advances, and Success Stories
While representing a significant portion of the available drugs on the market, the pharmaceutical industry has, until relatively recently, been reluctant to deliberately design covalent drugs. Read the article by Andrew Ratcliffe and Scott Martin of Domainex in IPI magazine here.

Venture Capital Term Sheet Guide 2025
The 2025 Venture Capital Term Sheet Guide, HSBC's third in the annual series, aims to empower founders with an objective view of deal information to enable them to negotiate the market with confidence. Read the report here.

Drug Discovery Goes Multimodal: The Evolving Design Continuum
ON Helix presents a unique opportunity to explore cutting-edge approaches to drug discovery. This year, at ON Helix, Arctoris will highlight how the convergence of biology, technology, and transformative tools like AI are expanding the scope and impact of drug discovery, such as driving innovation through new modalities as set out in its article; Drug Discovery Goes Multimodal: The Evolving Design Continuum. Read the article here.



One Nucleus Events | Training Courses | Industry News

Corporate Patron

AstraZeneca

Corporate Sponsors

CHESTERFORD RESEARCH PARK

ThermoFisher SCIENTIFIC

MSD

Copyright © 2025
One Nucleus is an international membership organisation for life science and healthcare companies.